SCN1A and Dravet syndrome: Sourbron et al. (2016) were able to demonstrate that selective 5-HT1D-, 5-HT1E-, 5-HT2A-, 5-HT2C-, and 5-HT7-R agonists significantly decreased epileptiform activity in a homozygous sodium voltage gated channel alpha subunit 1 (SCN1A) mutant zebrafish model for Dravet syndrome (Sourbron et al., 2016).